Signaling through the insulin-like growth factor 1 receptor (IGF-1R) is increasingly recognized as a precursor to and a potentiator of the malignant phenotype in preclincal models. The axis of proteins involved is complex, including two ligands, six binding proteins, IGF-1R, and IGF-2R, a non-signaling receptor, and two adaptor proteins. Circulating levels or tumor expression of IGF axis proteins has been correlated with risk of malignancy or poor prognosis of established cancer. IGF-1R interacts with other cellular receptors including epidermal growth factor receptor (EGFR), a validated drug target in HNSCC. We have observed that activation of IGF-1R signaling in cell lines promotes proliferation, survival, angiogenesis and invasion. Further, our data indicate that activation of IGF-1R can mediate resistance to EGF-R-targeted therapy and vice versa, suggesting an advantage to co-targeting EGFR and IGF-1 R. Thus, we hypothesize that cotargeting IGF-1 R and EGFR will be more successful than inhibition of either pathway alone in therapy of HNSCC. In this project, we will assess IGF axis protein expression and downstream proteins in tumor microarrays from patients resected for SCC of the oral tongue (Aim 1). Correlation of biomarkers with disease-specific survival will be explored, especially as regards the negative impact of nodal spread and extracapsular invasion, an invasive phenotype. We will study cooperation of IGF-1 R and EGFR in mediating proliferative, angiogenic, and invasive activities of HNSCC lines in vitro (Aim 2). Antitumor effects of the anti- IGF-1R humanized monoclonal antibody (IMC-A12) will be studied alone or with anti-EGFR antibody cetuximab, using multiple complementary models, including a highly metastatic cell line, in orthotopic tongue xenograft models (Aim 3). The activity of IMC-A12 as monotherapy or combined with cetuximab will be defined in a randomized trial for patients with recurrent HNSCC (Aim 4), targeting a 50% improvement in progression-free survival compared to cetuximab alone. Tissue and blood-based biomarkers will be assessed and correlations with clinical outcomes explored. This proposal builds on our results implicating IGF axis signaling in potentiating the malignant phenotype of HNSCC and promising data co-targeting EGFR and IGF-1 R in therapy of HNSCC. Insights to be gained from this work, both preclincal and clinical aims, have the potential to facilitate targeting therapy to those patients most likely to benefit.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097007-10
Application #
8380167
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
2014-07-31
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
10
Fiscal Year
2012
Total Cost
$343,462
Indirect Cost
$108,627
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Papadimitrakopoulou, Vasiliki A; Frank, Steven J; Cohen, Ezra W et al. (2016) Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head Neck 38:439-47
Green, E K; Rees, E; Walters, J T R et al. (2016) Copy number variation in bipolar disorder. Mol Psychiatry 21:89-93
Rupaimoole, Rajesha; Calin, George A; Lopez-Berestein, Gabriel et al. (2016) miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discov 6:235-46
Skinner, Heath D; Giri, Uma; Yang, Liang et al. (2016) Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer. Clin Cancer Res 22:4643-50
Bharadwaj, Uddalak; Eckols, T Kris; Xu, Xuejun et al. (2016) Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget 7:26307-30
Hu, Jianhua; Zhang, Liwen; Wang, Huixia Judy (2016) Sequential model selection-based segmentation to detect DNA copy number variation. Biometrics 72:815-26
Walline, Heather M; Carey, Thomas E; Goudsmit, Christine M et al. (2016) High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Mol Cancer Res :
Johnson, Eric O; Hancock, Dana B; Levy, Joshua L et al. (2016) KAT2B polymorphism identified for drug abuse in African Americans with regulatory links to drug abuse pathways in human prefrontal cortex. Addict Biol 21:1217-1232
Liu, Zhensheng; Liu, Hongliang; Gao, Fengqin et al. (2016) Reduced DNA double-strand break repair capacity and risk of squamous cell carcinoma of the head and neck--A case-control study. DNA Repair (Amst) 40:18-26
Ling, Hui; Pickard, Karen; Ivan, Cristina et al. (2016) The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut 65:977-89

Showing the most recent 10 out of 319 publications